Daniel Menold is President & VP at CymaBay Therapeutics, Inc. (CBAY). They have made 1 open-market trade across 1 company since 2018, most recently 2024-01-16.
CIK 0001705745
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CBAY | 10,000 | $325K |
Shares reported on the most recent Form 4, priced at the 2024-01-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CBAY | SELL · 10b5-1 | 2024-01-16 | 2024-01-16 | $23.58 | $472K | -2.9% | +35.7% | N/A |
| CBAY | SELL · 10b5-1 | 2023-12-15 | 2023-12-15 | $21.99 | $725K | +10.8% | +11.9% | +50.0% |
| CBAY | SELL · 10b5-1 | 2023-08-09 | 2023-08-11 | $12.35 | $517K | +1.4% | +25.7% | +9.0% |
| CBAY | SELL | 2018-08-29 | 2018-08-31 | $13.00 | $65K | -6.9% | -19.7% | -33.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.